Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Frespaciguat in Pulmonary Arterial Hypertension
NCT04732221Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- May 2021
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 18
01
Overview
A Phase 3 trial of frespaciguat in pulmonary arterial hypertension (PAH), sponsored by Merck & Co.. Started May 2021; status: completed.
02
Drugs
frespaciguat
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT04732221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04732221.